The Lancet. Microbe · 2027
Accelerating the clinical development of treatments for dengue: WHO dengue therapeutics landscape analysis and target product profiles.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chan Xin Hui S, Durbin Anna P, Malavige Gathsaurie Neelika, Baldanti Fausto, Cavaleri Marco, Chowdhury Fazle Rabbi, de Siqueira Isadora C, Hashmi Madiha, Huynh Trung Trieu, Low Jenny G, Madani Tariq A, Neyts Johan, Thisyakorn Usa, Valderrama-Beltrán Sandra L, Diaz Janet V, Moorthy Vasee, Penazzato Martina, Rojas Diana P, Velayudhan Raman
Аннотация
Dengue, an Aedes mosquito-borne viral infection, is on the rise with climate and demographic change. In 2023, WHO declared dengue its highest grade of emergency, following the largest number of cases and deaths in recorded history. This emergency highlighted the absence of safe and effective dengue-specific treatments as a gap in the product landscape for care for people with dengue. To accelerate development of dengue-specific treatments for wide implementation and access in all dengue-endemic countries, WHO conducted a landscape analysis of the dengue therapeutics pipeline and convened a global expert and public consultation to develop target product profiles for treatments for non-severe and severe dengue. These target product profiles provide strategic guidance for product developers, regulators, procurement agencies, and funders on the intended use, target populations, and key product characteristics of dengue-specific treatments required to meet public health needs, setting clear targets to drive development of dengue drugs accessible to those who need them the most.